Search research articles
Contact Us
Filters
Showing results (291-300 of 483) with videos related to
Page
of 49
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
September 27, 2022
Transcriptomic Profiling Identifies CD8<sup>+</sup> T Cells in the Brain of Aged and Alzheimer's Disease Transgenic Mice as Tissue-Resident Memory T Cells
Barbara Altendorfer, Michael Stefan Unger, Rodolphe Poupardin, et al.
Annals of Hematology
|
June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
Alexander Egle, Michael Steurer, Thomas Melchardt, et al.
Cancer Research
|
February 4, 2016
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia
Peter W Krenn, Sebastian W Hofbauer, Susanne Pucher, et al.
BMC Cancer
|
November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Wiener Klinische Wochenschrift
|
June 14, 2020
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study
Andreas L Petzer, Wolfgang R Sperr, Veronika Buxhofer-Ausch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, et al.
Ejhaem
|
July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)
Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
ACS Omega
|
January 8, 2026
Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation
Ana Rs Ribeiro, Ander Eguskiza, Hieu-Hoa Dang, et al.
Acta Haematologica
|
February 25, 2024
Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature
Thomas Parigger, Stephan Drothler, Christian Scherhäufl, et al.
Blood
|
January 21, 2018
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia
Julia C Gutjahr, Eva Szenes, Lisa Tschech, et al.
Page
of 49
Search research articles
Search
Showing results (291-300 of 483) with videos related to
Sort By:
Page
of 49
Journal of Immunology (Baltimore, Md. : 1950)
|
September 27, 2022
Transcriptomic Profiling Identifies CD8<sup>+</sup> T Cells in the Brain of Aged and Alzheimer's Disease Transgenic Mice as Tissue-Resident Memory T Cells
Barbara Altendorfer, Michael Stefan Unger, Rodolphe Poupardin, et al.
Annals of Hematology
|
June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
Alexander Egle, Michael Steurer, Thomas Melchardt, et al.
Cancer Research
|
February 4, 2016
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia
Peter W Krenn, Sebastian W Hofbauer, Susanne Pucher, et al.
BMC Cancer
|
November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Wiener Klinische Wochenschrift
|
June 14, 2020
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study
Andreas L Petzer, Wolfgang R Sperr, Veronika Buxhofer-Ausch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, et al.
Ejhaem
|
July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)
Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
ACS Omega
|
January 8, 2026
Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation
Ana Rs Ribeiro, Ander Eguskiza, Hieu-Hoa Dang, et al.
Acta Haematologica
|
February 25, 2024
Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature
Thomas Parigger, Stephan Drothler, Christian Scherhäufl, et al.
Blood
|
January 21, 2018
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia
Julia C Gutjahr, Eva Szenes, Lisa Tschech, et al.
Page
of 49